Biocon Partner Duopharma Secures Malaysia Health Ministry Insulin Contracts Worth Over MYR 225 Million

Biocon Ltd on June 24, 2026, announced that Duopharma Biotech Berhad, its partner, has been awarded insulin supply contracts worth more than MYR 225 million by Malaysia’s Ministry of Health, as per an exchange filing dated June 24, 2026.  

The contracts cover recombinant human insulin, insulin glargine, and insulin aspart, which are used in the treatment of diabetes. Supplies under the agreements will be made through Biocon’s Malaysian subsidiary. 

Breakdown of the Contracts 

According to the company, the largest contract is a 3-year agreement worth about MYR 155.27 million for human insulin.  

The Ministry has also awarded a 2-year contract valued at around MYR 18 million for insulin glargine and another 2-year contract worth approximately MYR 52.5 million for insulin aspart. The combined value of the 3 contracts exceeds MYR 225 million. 

Biocon’s Partnership in Malaysia 

Biocon and Duopharma have been working together in Malaysia since 2016. Over this period, more than 120 million insulin cartridges have been supplied to facilities operated by the Ministry of Health.  

The companies said these supplies have supported over 450,000 patients receiving treatment through Malaysia’s public healthcare system. 

Diabetes Treatment Demand 

Malaysia continues to report a high number of diabetes cases. Data cited by the company from the International Diabetes Federation’s 11th Diabetes Atlas estimates that around 4.75 million people in the country are living with the condition. Government hospitals and healthcare centres remain key channels for insulin distribution in the country. 

Biocon’s Manufacturing Facility 

The insulin products covered under the contracts are manufactured at Biocon’s facility in Iskandar Puteri, Johor. The site produces recombinant human insulin as well as rapid-acting and long-acting insulin products.  

Biocon said it has invested more than $600 million in the facility since 2011. The plant employs over 1,100 people and supplies products to Malaysia and other markets. 

Read More: Axis Bank Share Price in Focus After Raising $800 Million Through a Dual-Tranche Dollar Bond Issue! 

Biocon Share Price Performance  

As of June 24, 2026, 11:16 am, Biocon Ltd share price was trading at ₹422.45, down 0.18% from the previous closing price. 

Conclusion 

The contracts, valued at over MYR 225 million, cover the supply of three insulin products to Malaysia’s public healthcare system. The agreements will run for two to three years and continue an existing supply arrangement between Duopharma and Biocon. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.